

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS, INC.,
et al.,¹

Debtors.

Chapter 11

Case No. 23-90085 (CML)

(Jointly Administered)

**SUMMARY COVERSHEET TO THE THIRD INTERIM APPLICATION OF
NORTON ROSE FULBRIGHT US LLP FOR ALLOWANCE OF COMPENSATION
FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES
INCURRED AS TEXAS COUNSEL TO THE OFFICIAL COMMITTEE OF
UNSECURED CREDITORS FOR THE PERIOD FROM SEPTEMBER 1, 2023
THROUGH AND INCLUDING NOVEMBER 30, 2023**

Name of Applicant:	Norton Rose Fulbright US LLP (“NRF”)	
Applicant’s Role in Case:	Texas Counsel to Official Committee of Unsecured Creditors	
Docket No. of Employment Order(s):	April 24, 2023, <i>effective as of</i> March 7, 2023 [Dkt. No. 514]	
Interim Application (X) No. 3 Final Application ()	Indicate whether this is an interim or final Application. If interim, indicate the number (1 st , 2 nd , 3 rd , etc.)	
	Beginning Date	End Date
Time period covered by this Application for which interim compensation has not previously been awarded:	9/1/2023	11/30/2023
Were the services provided necessary to the administration of or beneficial at the time rendered toward the completion of the case? (Y)		
Were the services performed in a reasonable amount of time commensurate with the complexity, importance and nature of the issues addressed? (Y)		
Is the requested compensation reasonable based on the customary compensation charged by comparably skilled practitioners in other non-bankruptcy cases? (Y)		

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity’s federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors’ service address is: 4955 Directors Place, San Diego, CA 92121.

Do expense reimbursements represent actual and necessary expenses incurred? (Y)	
Compensation Breakdown for Time Period Covered by this Application	
Total professional fees requested in this Application:	\$81,778.00
Total professional hours covered by this Application:	91.10
Average hourly rate for professionals:	\$841.67
Total paraprofessional fees requested in this Application:	\$1,657.50
Total paraprofessional hours covered by this Application:	5.1
Average hourly rate for paraprofessionals:	\$325.00
Total fees requested in this Application:	\$83,435.50
Total expense reimbursements requested in this Application:	\$139.20
Total fees and expenses requested in this Application:	\$83,574.70
Total fees and expenses awarded in all prior Applications:	\$245,510.69
<p>Plan Status: On November 30, 2023, the Bankruptcy Court entered an order confirming the Debtors' chapter 11 plan of liquidation [Dkt. No. 1616]. The Debtors do not expect the plan to go effective until approximately April 2024.</p>	
<p>Primary Benefits: During the Chapter 11 case, NRF has assisted co-counsel, Milbank LLP, to diligently represent and advise the Committee on a variety of complex matters and issues, including various second day pleadings, debtor-in-possession financing, appointment of an equity committee, employment and retention matters, stock sales and procedures, Rule 2004 discovery, judicial mediation, asset sales including an auction and two sale hearings, disclosure statement drafting and negotiation, plan negotiation, plan confirmation, and post-confirmation issues, including pursuit of potential avoidance actions.</p>	

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS, INC.,
et al.,¹

Debtors.

Chapter 11

Case No. 23-90085 (DRJ)

(Jointly Administered)

**THIRD INTERIM APPLICATION OF NORTON ROSE FULBRIGHT US LLP FOR
ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND
REIMBURSEMENT OF EXPENSES INCURRED AS TEXAS COUNSEL TO THE
OFFICIAL COMMITTEE OF UNSECURED CREDITORS FOR THE PERIOD FROM
SEPTEMBER 1, 2023 THROUGH AND INCLUDING NOVEMBER 30, 2023**

**IF YOU OBJECT TO THE RELIEF REQUESTED, YOU MUST RESPOND
IN WRITING. UNLESS OTHERWISE DIRECTED BY THE COURT, YOU
MUST FILE YOUR RESPONSE ELECTRONICALLY AT
[HTTPS://ECF.TXSB.USCOURTS.GOV/](https://ecf.txsb.uscourts.gov/) WITHIN TWENTY-ONE DAYS
FROM THE DATE THIS MOTION WAS FILED. IF YOU DO NOT HAVE
ELECTRONIC FILING PRIVILEGES, YOU MUST FILE A WRITTEN
OBJECTION THAT IS ACTUALLY RECEIVED BY THE CLERK
WITHIN TWENTY-ONE DAYS FROM THE DATE THIS MOTION WAS
FILED. OTHERWISE, THE COURT MAY TREAT THE PLEADING AS
UNOPPOSED AND GRANT THE RELIEF REQUESTED**

Pursuant to sections 330 and 331 of title 11 of the United States Code (the “Bankruptcy Code”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Rule 2016-1 of the Bankruptcy Local Rules for the Southern District of Texas (the “Bankruptcy Local Rules”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442] (the “Interim Compensation Order”), Norton Rose Fulbright US LLP (“NRF”) hereby submits its third interim fee application (this “Application”)

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity’s federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors’ service address is: 4955 Directors Place, San Diego, CA 92121.

for allowance of compensation for services rendered and reimbursement of expenses as Texas counsel to the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., *et al.*

In support of this Application, NRF attaches the following exhibits:

- **Exhibit A:** Seventh Monthly Fee Statement of Norton Rose Fulbright US LLP for Allowance of Compensation for Services Rendered and Reimbursement of Expenses Incurred as Texas Counsel to the Official Committee of Unsecured Creditors from September 1, 2023 to September 30, 2023
- **Exhibit B:** Eighth Monthly Fee Statement of Norton Rose Fulbright US LLP for Allowance of Compensation for Services Rendered and Reimbursement of Expenses Incurred as Texas Counsel to the Official Committee of Unsecured Creditors from October 1, 2023 to October 31, 2023
- **Exhibit C:** Ninth Monthly Fee Statement of Norton Rose Fulbright US LLP for Allowance of Compensation for Services Rendered and Reimbursement of Expenses Incurred as Texas Counsel to the Official Committee of Unsecured Creditors from November 1, 2023 to November 30, 2023

Dated: January 5, 2024
Houston, Texas

Respectfully submitted,

NORTON ROSE FULBRIGHT US LLP

By: /s/ Ryan Manns

Ryan Manns (SBT 240413914)

Julie G. Harrison (SBT 24092434)

1301 McKinney Street, Suite 5100

Houston, TX 77010

Telephone: (713) 651-5151

Facsimile: (713) 651-5246

Email: ryan.manns@nortonrosefulbright.com

Email: julie.harrison@nortonrosefulbright.com

*Texas Counsel for the Official Committee of
Unsecured Creditors*

CERTIFICATE OF SERVICE

I certify that on January 5, 2024, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Southern District of Texas.

/s/ Julie Harrison
Julie Harrison

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS, INC.,
ET AL.,¹

Debtors.

Chapter 11

Case No. 23-90085 (DRJ)

(Jointly Administered)

**SEVENTH MONTHLY FEE STATEMENT OF NORTON ROSE FULBRIGHT
US LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED
AND REIMBURSEMENT OF EXPENSES INCURRED AS TEXAS COUNSEL
TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FROM
SEPTEMBER 1, 2023 TO SEPTEMBER 30, 2023**

Name of applicant:	Norton Rose Fulbright US LLP
Role in case:	Texas Counsel to Official Committee of Unsecured Creditors
Date of retention:	April 24, 2023, <i>effective as of</i> March 7, 2023 [Dkt. No. 514]
Period covered:	September 1, 2023 through September 30, 2023
Fees incurred:	\$31,468.00
20% holdback:	\$6,293.60
Total fees incurred less 20% holdback:	\$25,174.40
Expenses incurred:	\$139.20
Total fees (80%) and expenses (100%) due: ²	\$25,313.60

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors' service address is: 4955 Directors Place, San Diego, CA 92121.

² Pursuant to this Court's *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442] (the "Interim Compensation Order"), if no objection to the fees or expenses sought in this Fee Statement is received by the expiration of the objection deadline, the Debtors are authorized to promptly pay 80% of the fees and 100% of the expenses identified in the Fee Statement.

In accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442], each party receiving notice of the monthly fee statement will have until 4:00 p.m. (Prevailing Central Time), 14 days after service of the monthly fee statement to object to the requested fees and expenses. Upon the expiration of such 14-day period, the Debtors are authorized to pay the Professional an amount of 80% of the fees and 100% of the expenses requested in the applicable monthly fee statement.

Norton Rose Fulbright US LLP (“NRF”), as Texas Counsel for the Committee, hereby files this monthly fee statement (the “Fee Statement”) for (a) compensation in the amount of \$25,174.40 (80% of \$31,468.00) for the reasonable and necessary legal services NRF rendered to the Committee from September 1, 2023 through and including September 30, 2023 (the “Compensation Period”) and (b) reimbursement for 100% of the actual and necessary expenses that NRF incurred in the amount of \$139.20 during the Compensation Period, for a total of \$25,313.60.

1. Attached as **Exhibit A** is a summary of hours and fees by task code.
2. Attached as **Exhibit B** is a summary of reimbursement sought by expense type for all expenses for the Compensation Period incurred in connection with the performance of professional services.
3. Attached as **Exhibit C** is NRF’s itemized time records of its professionals and paraprofessionals and itemized records of reimbursement sought for the Compensation Period.
4. This Monthly Fee Statement includes all the information and supporting detail regarding fees and expenses available to NRF at the time of the filing of this Monthly Fee Statement. If additional information and supporting detail in connection with this Compensation Period should become available, as a result of delays in accounting processing or an inadvertence with respect to time or expenses entered in the accounting system, or any other reason, NRF

reserves the right to make an application to the Court for an allowance of such fees and expenses not included in this Monthly Statement.

WHEREFORE, NRF, in connection with services rendered on behalf of the Committee, respectfully requests (a) allowance of compensation and reimbursement in the amount of (i) \$25,174.40 (80% of \$31,468.00) and (ii) \$139.20 for 100% of actual and necessary costs and expenses incurred during the Compensation Period and (b) payment of the forgoing sums.

Dated: October 10, 2023
Houston, Texas

Respectfully submitted,

NORTON ROSE FULBRIGHT US LLP

By: /s/ Ryan Manns
Ryan Manns (SBT 240413914)
Julie G. Harrison (SBT 24092434)
1301 McKinney Street, Suite 5100
Houston, TX 77010
Telephone: (713) 651-5151
Facsimile: (713) 651-5246
Email: ryan.manns@nortonrosefulbright.com
Email: julie.harrison@nortonrosefulbright.com

*Texas Counsel for the Official Committee of
Unsecured Creditors*

CERTIFICATE OF SERVICE

I certify that on October 10, 2023, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Southern District of Texas.

/s/ Julie Harrison
Julie Harrison

EXHIBIT A**COMPENSATION BY PROJECT CATEGORY
SEPTEMBER 1, 2023 THROUGH SEPTEMBER 30, 2023**

Project Category	Total Hours	Total Fees
B110: Case Administration	9.3	\$8,594.50
B130: Asset Disposition	2.8	\$2,512.00
B150: Meetings of and Communications with Creditors	16.9	\$15,371.00
B160: Employment and Fee Applications	5.1	\$3,763.50
B170: Employment and Fee Objections	0.5	\$475.00
B230: Financing and Cash Collateral	0.8	\$752.00
TOTAL	35.4	\$31,468.00

EXHIBIT B

**EXPENSES FOR
SEPTEMBER 1, 2023 THROUGH SEPTEMBER 30, 2023**

Description	Amount
Transcript	\$139.20
Total:	\$139.20

EXHIBIT C

TIME DETAIL

INVOICE

Case 23-90085 Document 1732 Filed 11/15/23 Entered in TXS on 11/15/23 Page 12 of 15

NORTON ROSE FULBRIGHT

Invoice Number 9495475837
Matter Number 1001247357
Invoice Date October 09, 2023
NRF Contact Ryan E. Manns

Norton Rose Fulbright US LLP
2200 Ross Avenue, Suite 3600
Dallas TX 75201
Tel: +1 214-855-8000
Fax: +1 214-855-8200
www.nortonrosefulbright.com
Tax ID No. 74-1201087
Accounts Contact:
nrfusaccountsreceivable@nortonrosefulbright.com

**Official Committee of Unsecured
Creditors of Sorrento Therapeutics**
3530 John Hopkins Ct.
San Diego CA 92121

Sorrento Therapeutics Bankruptcy

Professional Services Rendered to September 30, 2023

Charges
USD

SUMMARY

Fees	31,468.00
Disbursements	139.20
TOTAL AMOUNT DUE AND PAYABLE	USD 31,607.20

Payable Upon Receipt
PAYMENT INFORMATION – Please reference the invoice number when remitting payment.

ELECTRONIC TRANSFER: to the account of Norton Rose Fulbright US LLP | HSBC | 452 5th Avenue, New York, NY 10018 | Wire Routing Number 021001088 |
ACH Routing Number 022000020 | SWIFT MRMDUS33 | CHIPS ABA: 0108 | Account Number 827023227 ||
MAIL: Norton Rose Fulbright US LLP, Dept. 2613 | PO Box 122613 Dallas, TX 75312-2613 ||

This invoice may include fees and disbursements of the member firms of the Norton Rose Fulbright Verein.

Please be alert to the risks of cyber-crime and email impersonation attempts to redirect funds inappropriately. We will not under usual circumstances change our bank account details during the course of a transaction. Any communication which you receive advising otherwise could be fraudulent and should urgently be orally verified with your known contact at our firm, or a member of our Finance department.

Invoice Date	October 09, 2023	Invoice Number	9495475837	Page	2
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

TIME DETAILS

<u>DATE</u>	<u>NAME</u>	<u>HOURS</u>	<u>DESCRIPTION</u>
09/01/2023	Harrison, J	1.80	Call with UCC and EC (1.3); related follow up with UCC (.5).
09/01/2023	Harrison, J	0.10	Confer with R. Manns and M. Tehrani regarding fee statements.
09/01/2023	Manns, R	1.20	Committee call with equity committee professionals.
09/01/2023	Manns, R	0.50	Participate on Committee call.
09/03/2023	Manns, R	0.20	Attention to multiple working group emails regarding sale updates and developments.
09/06/2023	Manns, R	0.10	Emails with Debtors' financial advisor regarding budget issues.
09/07/2023	Harrison, J	0.70	Attend UCC call.
09/07/2023	Harrison, J	0.30	Attention to numerous correspondence regarding mediation update.
09/07/2023	Manns, R	0.20	Attend call to discuss mediation update.
09/07/2023	Manns, R	0.80	Attend and participate on Committee call.
09/08/2023	Harrison, J	0.80	Attend mediation update call (.7); analysis of emails regarding same (.1).
09/08/2023	Harrison, J	0.10	Confer with M. Haverkamp regarding fee statement.
09/08/2023	Manns, R	1.00	Attend and participate on mediation update calls.
09/09/2023	Manns, R	0.10	Attention to multiple working group emails regarding status of mediation and sale negotiation updates.
09/10/2023	Manns, R	0.30	Review and analyze draft term sheet (.2); attention to multiple update emails regarding sale updates (.1).
09/11/2023	Mokrzycka, M	1.30	Review and revise BRG fee statement and file the same (.3); draft, revise, and file fourth monthly fee statement of NRF (.9); communication with R. Manns regarding the same (.1).
09/11/2023	Manns, R	0.30	Review emergency motion to approve Scilex sale.
09/11/2023	Manns, R	0.20	Multiple working group emails regarding fee statements.
09/11/2023	Manns, R	0.10	Review hearing agenda and witness and exhibit lists.
09/11/2023	Harrison, J	0.20	Analysis of emergency Scilex sale motion.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	October 09, 2023	Invoice Number	9495475837	Page	3
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

09/12/2023	Adams, K	0.30	Review bankruptcy docket; review Emergency Motion regarding objection to fees; update hearing information.
09/12/2023	Harrison, J	0.80	Attend sale hearing.
09/12/2023	Manns, R	0.90	Attend sale to Scilex approval hearing.
09/13/2023	Harrison, J	0.10	Analysis of withdrawal of objection to professional fees.
09/13/2023	Manns, R	0.20	Review status update and Committee call agenda.
09/13/2023	Manns, R	0.30	Emails regarding fee statements (.1); revisions to same (.2).
09/13/2023	Mokrzycka, M	1.40	Draft CNO for BRG fee application (.3); draft NRF's fifth monthly fee statement and file the same (.9); file NRF and Milbank fee statements (.1).
09/14/2023	Manns, R	0.40	Attend contested fee hearing.
09/14/2023	Manns, R	0.90	Attend and participate on Committee call.
09/18/2023	Manns, R	0.20	Working group emails regarding second interim fee application.
09/19/2023	Boland, J	0.20	Various emails with R. Manns regarding case update and [REDACTED].
09/19/2023	Harrison, J	0.10	Confer with K. Sommerfeld regarding fee application.
09/19/2023	Manns, R	1.20	Review and analyze [REDACTED] (.9); and multiple emails with working group regarding same (.3).
09/20/2023	Harrison, J	0.40	Draft second interim fee statement.
09/20/2023	Manns, R	2.00	Research on [REDACTED].
09/21/2023	Manns, R	0.20	Review draft interim fee application.
09/21/2023	Manns, R	0.90	Attend and participate on Committee call.
09/21/2023	Manns, R	0.30	Review draft [REDACTED].
09/21/2023	Manns, R	0.10	Attention to BRG wind down materials and asset sale update.
09/21/2023	Manns, R	1.50	Revisions to [REDACTED] (.8); research in SDTX regarding same (.4); multiple emails with working group (.3)
09/21/2023	Harrison, J	0.80	Research regarding [REDACTED] (.7); and related correspondence with R. Manns (.1).
09/21/2023	Harrison, J	0.10	Confer with M. Tehrani and R. Manns regarding fee statements.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	October 09, 2023	Invoice Number	9495475837	Page	4
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

09/21/2023	Harrison, J	0.90	Attend UCC call.
09/21/2023	Boland, J	0.20	Various emails with team regarding [REDACTED] and preliminary review of same.
09/21/2023	Adams, K	0.20	Review bankruptcy docket regarding recent filings; prepare update regarding emergency motion to extend exclusivity period.
09/22/2023	Harrison, J	0.60	Revise and file Milbank fee statement (.2); finalize and file Milbank and NRF fee applications (.4).
09/22/2023	Harrison, J	0.40	Attend UCC call.
09/22/2023	Harrison, J	0.30	Confer with R. Manns regarding [REDACTED]
09/22/2023	Harrison, J	0.30	Analysis of draft [REDACTED] (.2); and related correspondence with R. Manns (.1).
09/22/2023	Manns, R	0.60	Call and multiple emails with Mr. Duran regarding [REDACTED] (.4); multiple emails with working group regarding same (.2).
09/22/2023	Manns, R	0.50	Revision to [REDACTED] (3); call and working group emails regarding same (.2).
09/22/2023	Manns, R	0.30	Analyze notice of circumstance.
09/22/2023	Manns, R	0.50	Committee call to discuss latest developments.
09/24/2023	Harrison, J	0.20	Attention to correspondence regarding DIP proposal and other updates.
09/24/2023	Manns, R	0.20	Attention to multiple working group emails regarding status updates and potential new DIPs.
09/24/2023	Manns, R	0.50	Review of local rules governing [REDACTED] (.3); email with Committee regarding notice and hearing issues (.2).
09/25/2023	Manns, R	0.20	Attention to BRG DIP analysis.
09/25/2023	Manns, R	0.60	Committee call to discuss update on DIP and next steps.
09/25/2023	Harrison, J	0.70	Attend UCC call.
09/26/2023	Harrison, J	0.10	Confer with R. Manns regarding [REDACTED]
09/26/2023	Harrison, J	0.70	Attend UCC call.
09/26/2023	Manns, R	0.80	Attend and participate on Committee call.
09/26/2023	Manns, R	0.50	Review and respond to multiple strategy emails concerning [REDACTED] (.4); review local rules regarding [REDACTED] (.1)

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.



Invoice Date October 09, 2023 **Invoice Number** 9495475837 **Page** 5
Matter Number 1001247357
Matter Description Sorrento Therapeutics Bankruptcy

09/26/2023	Manns, R	0.50	Review and respond to multiple working group emails regarding [REDACTED] (.3); attention to [REDACTED] (.2).
09/26/2023	Manns, R	0.20	Review of draft DIP term sheet.
09/27/2023	Harrison, J	0.10	Analysis of UCC agenda.
09/27/2023	Manns, R	0.10	Review Committee call agenda.
09/27/2023	Manns, R	0.10	Review Committee mark-up of DIP term sheet.
09/28/2023	Harrison, J	0.50	Attend UCC call.
09/28/2023	Manns, R	0.50	Participate on Committee call.
09/29/2023	Harrison, J	0.10	File Shinderman declaration.
09/29/2023	Harrison, J	0.20	Analysis of update from M. Shinderman.
09/29/2023	Manns, R	0.20	Attention to multiple working group status email updates.
Total		35.40	

DISBURSEMENT SUMMARY

<u>DATE</u>	<u>DESCRIPTION</u>	<u>AMOUNT</u>
08/31/2023	010061396000 - Adams, Kim - Ordered Transcript	139.20
Sub Total		139.20
TOTAL		139.20

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS, INC.,
ET AL.,¹

Debtors.

Chapter 11

Case No. 23-90085 (CML)

(Jointly Administered)

**EIGHTH MONTHLY FEE STATEMENT OF NORTON ROSE FULBRIGHT
US LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED
AND REIMBURSEMENT OF EXPENSES INCURRED AS TEXAS COUNSEL
TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FROM
OCTOBER 1, 2023 TO OCTOBER 31, 2023**

Name of applicant:	Norton Rose Fulbright US LLP
Role in case:	Texas Counsel to Official Committee of Unsecured Creditors
Date of retention:	April 24, 2023, <i>effective as of</i> March 7, 2023 [Dkt. No. 514]
Period covered:	October 1, 2023 through October 31, 2023
Fees incurred:	\$27,841.00
20% holdback:	\$5,568.20
Total fees incurred less 20% holdback:	\$22,272.80
Expenses incurred:	\$0.00
Total fees (80%) and expenses (100%) due: ²	\$22,272.80

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors' service address is: 4955 Directors Place, San Diego, CA 92121.

² Pursuant to this Court's *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442] (the "Interim Compensation Order"), if no objection to the fees or expenses sought in this Fee Statement is received by the expiration of the objection deadline, the Debtors are authorized to promptly pay 80% of the fees and 100% of the expenses identified in the Fee Statement.

In accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442], each party receiving notice of the monthly fee statement will have until 4:00 p.m. (Prevailing Central Time), 14 days after service of the monthly fee statement to object to the requested fees and expenses. Upon the expiration of such 14-day period, the Debtors are authorized to pay the Professional an amount of 80% of the fees and 100% of the expenses requested in the applicable monthly fee statement.

Norton Rose Fulbright US LLP (“NRF”), as Texas Counsel for the Committee, hereby files this monthly fee statement (the “Fee Statement”) for compensation in the amount of \$22,272.80 (80% of \$27,841.00) for the reasonable and necessary legal services NRF rendered to the Committee from October 1, 2023 through and including October 31, 2023 (the “Compensation Period”).

1. Attached as **Exhibit A** is a summary of hours and fees by task code.
2. Attached as **Exhibit B** is NRF’s itemized time records of its professionals and paraprofessionals for the Compensation Period.
3. This Monthly Fee Statement includes all the information and supporting detail regarding fees and expenses available to NRF at the time of the filing of this Monthly Fee Statement. If additional information and supporting detail in connection with this Compensation Period should become available, as a result of delays in accounting processing or an inadvertence with respect to time or expenses entered in the accounting system, or any other reason, NRF reserves the right to make an application to the Court for an allowance of such fees and expenses not included in this Monthly Statement.

WHEREFORE, NRF, in connection with services rendered on behalf of the Committee, respectfully requests (a) allowance of compensation and reimbursement in the amount of \$22,272.80 (80% of \$27,841.00) and (b) payment of the forgoing sums.

Dated: December 4, 2023
Houston, Texas

Respectfully submitted,

NORTON ROSE FULBRIGHT US LLP

By: /s/ Ryan Manns

Ryan Manns (SBT 240413914)

Julie G. Harrison (SBT 24092434)

1301 McKinney Street, Suite 5100

Houston, TX 77010

Telephone: (713) 651-5151

Facsimile: (713) 651-5246

Email: ryan.manns@nortonrosefulbright.com

Email: julie.harrison@nortonrosefulbright.com

*Texas Counsel for the Official Committee of
Unsecured Creditors*

CERTIFICATE OF SERVICE

I certify that on December 4, 2023, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Southern District of Texas.

/s/ Julie Harrison

Julie Harrison

EXHIBIT A**COMPENSATION BY PROJECT CATEGORY
OCTOBER 1, 2023 THROUGH OCTOBER 31, 2023**

Project Category	Total Hours	Total Fees
B110: Case Administration	3.6	\$3,197.50
B130: Asset Disposition	0.6	\$514.00
B150: Meetings of and Communications with Creditors	10.7	\$9,533.00
B160: Employment and Fee Applications	5.3	\$3,132.50
B180: Avoidance Action Analysis	1.4	\$1,163.50
B190: Other Contested Matters	0.7	\$413.50
B230: Financing and Cash Collateral	0.4	\$396.00
B310: Claims Administration and Objections	0.2	\$125.00
B320: Plan and Disclosure Statement	10.4	\$8,772.00
B410: General Bankruptcy Advice/Opinions	0.6	\$594.00
TOTAL	33.9	\$27,841.00

EXHIBIT B

TIME DETAIL

INVOICE

Case 23-90085 Document 1736 Filed 11/23/23 Entered in TXSB on 11/23/23 Page 22 of 135

NORTON ROSE FULBRIGHT

Invoice Number 9495484023
Matter Number 1001247357
Invoice Date November 10, 2023
NRF Contact Ryan E. Manns

Norton Rose Fulbright US LLP
2200 Ross Avenue, Suite 3600
Dallas TX 75201
Tel: +1 214-855-8000
Fax: +1 214-855-8200
www.nortonrosefulbright.com
Tax ID No. 74-1201087
Accounts Contact:
nrfusaccountsreceivable@nortonrosefulbright.com

**Official Committee of Unsecured
Creditors of Sorrento Therapeutics**
3530 John Hopkins Ct.
San Diego CA 92121

Sorrento Therapeutics Bankruptcy

Professional Services Rendered to October 31, 2023

Charges
USD

SUMMARY

Fees	27,841.00
TOTAL AMOUNT DUE AND PAYABLE	USD 27,841.00

Payable Upon Receipt**PAYMENT INFORMATION** – Please reference the invoice number when remitting payment.

ELECTRONIC TRANSFER: to the account of Norton Rose Fulbright US LLP | HSBC | 452 5th Avenue, New York, NY 10018 | Wire Routing Number 021001088 |
ACH Routing Number 022000020 | SWIFT MRMDUS33 | CHIPS ABA: 0108 | Account Number 827023227 ||
MAIL: Norton Rose Fulbright US LLP, Dept. 2613 | PO Box 122613 Dallas, TX 75312-2613 ||

This invoice may include fees and disbursements of the member firms of the Norton Rose Fulbright Verein.

Please be alert to the risks of cyber-crime and email impersonation attempts to redirect funds inappropriately. We will not under usual circumstances change our bank account details during the course of a transaction. Any communication which you receive advising otherwise could be fraudulent and should urgently be orally verified with your known contact at our firm, or a member of our Finance department.

Invoice Date	November 10, 2023	Invoice Number	9495484023	Page	2
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

TIME DETAILS

<u>DATE</u>	<u>NAME</u>	<u>HOURS</u>	<u>DESCRIPTION</u>
10/02/2023	Manns, R	0.10	Emails with Debtors' financial advisor re: budget issues.
10/03/2023	Harrison, J	1.00	Attend UCC call.
10/03/2023	Harrison, J	0.10	Analysis of update from M. Shinderman.
10/03/2023	Manns, R	1.00	Attend and participate on Committee call.
10/04/2023	Manns, R	0.20	Review and analyze multiple status update emails.
10/04/2023	Manns, R	0.10	Review Committee call agenda.
10/05/2023	Manns, R	0.10	Review and respond to creditor email re: contract assumption/rejection issues.
10/05/2023	Manns, R	0.80	Attend status conference.
10/05/2023	Manns, R	0.10	Attention to Ovydsco sale updates.
10/05/2023	Manns, R	0.90	Participate on Committee call.
10/05/2023	Harrison, J	0.40	Attend status conference.
10/05/2023	Harrison, J	0.80	Attend UCC call.
10/06/2023	Manns, R	0.10	Review of Scilex term sheet.
10/06/2023	Manns, R	0.30	Review Debtors' illustrative restructuring overview.
10/06/2023	Manns, R	0.30	Review of equity committee term sheet.
10/08/2023	Harrison, J	0.20	Attention to updates from M. Schinderman.
10/08/2023	Harrison, J	0.10	Correspondence with M. Shinderman and R. Manns regarding fee apps.
10/08/2023	Manns, R	0.20	Review call agenda and multiple case updates.
10/08/2023	Manns, R	0.20	Review of equity committee term sheet.
10/09/2023	Manns, R	0.30	Call with estate creditor, KPS Life, re: case update and assumption and rejection issues.
10/09/2023	Manns, R	0.70	Review and respond to multiple working group emails re: wind down issues (.4); attention to preservation of claim actions in the Fifth Circuit (.3).
10/09/2023	Manns, R	0.30	Review and comment on draft fee statements (.2); working group emails re: same (.1).

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	November 10, 2023	Invoice Number	9495484023	Page	3
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

10/09/2023	Manns, R	1.10 Attend and participate on Committee call.
10/09/2023	Harrison, J	0.40 Draft NRF seventh fee statement.
10/09/2023	Harrison, J	1.20 Attend UCC call.
10/09/2023	Harrison, J	0.10 Confer with R. Manns regarding fee statement.
10/10/2023	Adams, K	0.50 Review and file NRF Seventh Monthly Fee Statement.
10/10/2023	Harrison, J	0.20 Correspondence with M. Tehrani and R. Manns regarding plan redline (.1); and analysis of same (.1).
10/10/2023	Harrison, J	0.70 Analysis of plan and disclosure statement redlines (.4); related correspondence with R. Manns (.1); call with M. Tehrani, R. Manns, and R. Rubin regarding same (.2).
10/10/2023	Manns, R	0.20 Review Yuhan sale motion.
10/10/2023	Manns, R	0.20 Review and respond to working group emails re: fee statement.
10/10/2023	Manns, R	0.90 Review of mark-up of liquidating plan (.4); attention to Fifth Circuit standard on preserving causes of action (.3); call with working group (.2).
10/10/2023	Manns, R	0.30 Attention to Debtors' mark-up of plan and disclosure statement.
10/11/2023	Adams, K	0.20 Review bankruptcy filings; update calendar.
10/11/2023	Harrison, J	0.40 Analysis of plan language regarding retained causes of action (.3); and related correspondence to Milbank team (.1).
10/11/2023	Harrison, J	0.20 Analysis of Yuhan sale motion.
10/11/2023	Manns, R	0.30 Review emergency motion to conditionally approve disclosure statement and related exhibits.
10/11/2023	Manns, R	0.10 Review draft call agenda.
10/12/2023	Manns, R	0.90 Attend and participate on Committee call.
10/12/2023	Manns, R	0.60 Review Fifth Circuit law on standing (.4); review of draft stipulation with the Debtors (.2)
10/12/2023	Manns, R	0.40 Review of filed plan and disclosure statement and emails related to same.
10/12/2023	Manns, R	0.10 Attention to liquidation analysis considerations in a chapter 11 vs. chapter 7.
10/12/2023	Harrison, J	0.70 Attend UCC call.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	November 10, 2023	Invoice Number	9495484023	Page	4
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

10/13/2023	Adams, K	0.50	Organize and file BRG's Seventh Monthly Fee Statement and Second Interim Fee Application.
10/13/2023	Adams, K	0.80	Prepare draft proposed Order for BRG's Second Interim Fee Application.
10/13/2023	Adams, K	0.70	Review and revise BRG's Seventh Monthly Fee Statement and Second Interim Fee Application.
10/13/2023	Manns, R	0.30	Working group emails re: reassignment of case.
10/13/2023	Manns, R	0.30	Multiple emails with Milbank team re: fee statements (.2); review of same in advance of filing (.1).
10/13/2023	Manns, R	0.60	Multiple emails with BRG team re: fee statements and application (.30); review and comment on same (.2); review draft proposed order (.1).
10/16/2023	Harrison, J	0.20	Confer with M. Mokrzycka regarding CNOs (.1); related correspondence with M. Tehrani (.1).
10/16/2023	Harrison, J	0.20	Confer with E. Dexter regarding preference complaints (.1); related correspondence with M. Mokrzycka (.1).
10/16/2023	Manns, R	0.30	Working group emails re: preference actions and attention to comparable complaints from the SDTX.
10/16/2023	Manns, R	0.20	Review of Scilex term sheet and emails related to same.
10/16/2023	Mokrzycka, M	0.60	Draft, revise, and file CNOs for fee application.
10/16/2023	Mokrzycka, M	0.50	Review precedent regarding preference action in the Southern District of Texas and pull complaints.
10/17/2023	Harrison, J	0.50	Attend UCC call.
10/17/2023	Manns, R	0.40	Status update call with working group.
10/18/2023	Manns, R	1.00	Attend Sorrento conditional Disclosure Statement hearing.
10/18/2023	Harrison, J	1.00	Attend disclosure statement hearing.
10/18/2023	Harrison, J	0.30	Analysis of redlined disclosure statement and plan.
10/18/2023	Adams, K	0.30	Prepare and file hearing transcript request.
10/19/2023	Adams, K	0.30	Review and file Stipulation regarding B. Riley Commercial claims.
10/19/2023	Harrison, J	0.50	Attend UCC call.
10/19/2023	Manns, R	0.20	Review of draft standing stipulation in advance of filing.
10/19/2023	Manns, R	0.50	Attend and participate on Committee call.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.



Invoice Date	November 10, 2023	Invoice Number	9495484023	Page	5
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

10/19/2023	Mokrzycka, M	0.20	Review stipulation regarding standing and confer with J. Harrison regarding the same.
10/23/2023	Harrison, J	0.10	Analysis of update from M. Shinderman.
10/23/2023	Manns, R	0.20	Review Committee correspondence to counsel for B. Riley re: preference allegations and standing stipulation.
10/25/2023	Manns, R	0.10	Attention to summary email update re: sale/plan status.
10/25/2023	Harrison, J	0.10	Analysis of update from M. Shinderman.
10/26/2023	Harrison, J	0.10	Analysis of update from M. Shinderman.
10/27/2023	Harrison, J	0.40	Confer with L. Towe regarding liquidation trust agreement; related correspondence to R. Rubin.
10/27/2023	Lawton, C	0.40	Discussion with L. Towe regarding trust issues.
10/27/2023	Manns, R	0.70	Review of proposed Liquidating Trust agreement (.4); analysis of proposed revisions from L. Towe (.3).
10/27/2023	Mokrzycka, M	0.20	Review application to employ , employment order regarding increase of rates.
10/27/2023	Towe, L	1.80	Attention to correspondence from J. Harrison regarding trust questions (.1); review trust agreement regarding the same (.4); discuss with J. Harrison (.2); discuss with C. Lawton (.4); draft correspondence to J. Harrison regarding the same (.7).
10/29/2023	Harrison, J	0.10	Analysis of update from M. Shinderman.
10/31/2023	Harrison, J	0.20	Confer with L. Towe regarding trust agreement.
10/31/2023	Harrison, J	0.20	Analysis of hearing agenda (.1); and related correspondence with R. Manns (.1).
10/31/2023	Manns, R	0.10	Review 11/1 hearing agenda.
10/31/2023	Towe, L	0.80	Attention to trust questions from Millbank; draft correspondence regarding the same.
Total		33.90	

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF TEXAS
HOUSTON DIVISION**

In re:

SORRENTO THERAPEUTICS, INC.,
ET AL.,¹

Debtors.

Chapter 11

Case No. 23-90085 (CML)

(Jointly Administered)

**NINTH MONTHLY FEE STATEMENT OF NORTON ROSE FULBRIGHT
US LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED
AND REIMBURSEMENT OF EXPENSES INCURRED AS TEXAS COUNSEL
TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FROM
NOVEMBER 1, 2023 TO NOVEMBER 30, 2023**

Name of applicant:	Norton Rose Fulbright US LLP
Role in case:	Texas Counsel to Official Committee of Unsecured Creditors
Date of retention:	April 24, 2023, <i>effective as of</i> March 7, 2023 [Dkt. No. 514]
Period covered:	November 1, 2023 through November 30, 2023
Fees incurred:	\$24,126.50
20% holdback:	\$4,825.30
Total fees incurred less 20% holdback:	\$19,301.20
Expenses incurred:	\$0.00
Total fees (80%) and expenses (100%) due: ²	\$19,301.20

¹ The Debtor entities in these chapter 11 cases, along with the last four digits of each Debtor entity's federal tax identification number, are: Sorrento Therapeutics, Inc. (4842) and Scintilla Pharmaceuticals, Inc. (7956). The Debtors' service address is: 4955 Directors Place, San Diego, CA 92121.

² Pursuant to this Court's *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442] (the "Interim Compensation Order"), if no objection to the fees or expenses sought in this Fee Statement is received by the expiration of the objection deadline, the Debtors are authorized to promptly pay 80% of the fees and 100% of the expenses identified in the Fee Statement.

In accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Professionals* [Dkt. No. 442], each party receiving notice of the monthly fee statement will have until 4:00 p.m. (Prevailing Central Time), 14 days after service of the monthly fee statement to object to the requested fees and expenses. Upon the expiration of such 14-day period, the Debtors are authorized to pay the Professional an amount of 80% of the fees and 100% of the expenses requested in the applicable monthly fee statement.

Norton Rose Fulbright US LLP (“NRF”), as Texas Counsel for the Committee, hereby files this monthly fee statement (the “Fee Statement”) for compensation in the amount of \$19,301.20 (80% of \$24,126.50) for the reasonable and necessary legal services NRF rendered to the Committee from November 1, 2023 through and including November 30, 2023 (the “Compensation Period”).

1. Attached as **Exhibit A** is a summary of hours and fees by task code.
2. Attached as **Exhibit B** is NRF’s itemized time records of its professionals and paraprofessionals for the Compensation Period.
3. This Monthly Fee Statement includes all the information and supporting detail regarding fees and expenses available to NRF at the time of the filing of this Monthly Fee Statement. If additional information and supporting detail in connection with this Compensation Period should become available, as a result of delays in accounting processing or an inadvertence with respect to time or expenses entered in the accounting system, or any other reason, NRF reserves the right to make an application to the Court for an allowance of such fees and expenses not included in this Monthly Statement.

WHEREFORE, NRF, in connection with services rendered on behalf of the Committee, respectfully requests (a) allowance of compensation and reimbursement in the amount of \$19,301.20 (80% of \$24,126.50) and (b) payment of the forgoing sums.

Dated: January 5, 2024
Houston, Texas

Respectfully submitted,

NORTON ROSE FULBRIGHT US LLP

By: /s/ Ryan Manns

Ryan Manns (SBT 240413914)

Julie G. Harrison (SBT 24092434)

1301 McKinney Street, Suite 5100

Houston, TX 77010

Telephone: (713) 651-5151

Facsimile: (713) 651-5246

Email: ryan.manns@nortonrosefulbright.com

Email: julie.harrison@nortonrosefulbright.com

*Texas Counsel for the Official Committee of
Unsecured Creditors*

CERTIFICATE OF SERVICE

I certify that on January 5, 2024, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Southern District of Texas.

/s/ Julie Harrison

Julie Harrison

EXHIBIT A**COMPENSATION BY PROJECT CATEGORY
NOVEMBER 1, 2023 THROUGH NOVEMBER 30, 2023**

Project Category	Total Hours	Total Fees
B110: Case Administration	1.5	\$1,445.00
B120: Asset Analysis and Recovery	0.3	\$97.50
B130: Asset Disposition	0.2	\$158.00
B150: Meetings of and Communications with Creditors	4.5	\$4,195.00
B160: Employment and Fee Applications	2.6	\$2,214.00
B185: Assumption/Rejection of Leases and Contracts	0.3	\$97.50
B190: Other Contested Matters	2.4	\$2,036.50
B195: Non-Working Travel	4.0	\$3,960.00
B230: Financing and Cash Collateral	0.3	\$297.00
B320: Plan and Disclosure Statement	10.8	\$9,626.00
TOTAL	26.9	\$24,126.50

EXHIBIT B

TIME DETAIL

Invoice Number	9495495697	Norton Rose Fulbright US LLP
Matter Number	1001247357	2200 Ross Avenue, Suite 3600
Invoice Date	December 27, 2023	Dallas TX 75201
NRF Contact	Ryan E. Manns	Tel: +1 214-855-8000
		Fax: +1 214-855-8200
		www.nortonrosefulbright.com
		Tax ID No. 74-1201087
		Accounts Contact:
		nrfusaccountsreceivable@nortonrosefulbright.com

Official Committee of Unsecured
Creditors of Sorrento Therapeutics
3530 John Hopkins Ct.
San Diego CA 92121

Sorrento Therapeutics Bankruptcy

Professional Services Rendered to November 30, 2023	Charges
	USD
SUMMARY	
Fees	24,126.50
TOTAL AMOUNT DUE AND PAYABLE	USD 24,126.50

Payable Upon Receipt
PAYMENT INFORMATION – Please reference the invoice number when remitting payment.

ELECTRONIC TRANSFER: to the account of Norton Rose Fulbright US LLP | HSBC |452 5th Avenue, New York, NY 10018 | Wire Routing Number 021001088 |
ACH Routing Number 022000020 | SWIFT MRMDUS33 | CHIPS ABA: 0108 | Account Number 827023227 ||
MAIL: Norton Rose Fulbright US LLP, Dept. 2613 | PO Box 122613 Dallas, TX 75312-2613 ||

This invoice may include fees and disbursements of the member firms of the Norton Rose Fulbright Verein.

Please be alert to the risks of cyber-crime and email impersonation attempts to redirect funds inappropriately. We will not under usual circumstances change our bank account details during the course of a transaction. Any communication which you receive advising otherwise could be fraudulent and should urgently be orally verified with your known contact at our firm, or a member of our Finance department.

Invoice Date	December 27, 2023	Invoice Number	9495495697	Page	2
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

TIME DETAILS

<u>DATE</u>	<u>NAME</u>	<u>HOURS</u>	<u>DESCRIPTION</u>
11/01/2023	Harrison, J	0.20	Attend Yuhan sale hearing.
11/01/2023	Manns, R	0.10	Attention to Committee call agenda.
11/01/2023	Manns, R	0.20	Attend sale hearing.
11/01/2023	Manns, R	0.20	Attention to plan supplement for joint plan of liquidation.
11/02/2023	Harrison, J	0.80	Draft supplemental declaration (.6); related correspondence with R. Manns (.2).
11/02/2023	Harrison, J	0.10	Confer with R. Manns regarding supplemental disclosure.
11/02/2023	Harrison, J	0.80	Attend UCC call.
11/02/2023	Manns, R	0.90	Attend and participate on Committee call.
11/03/2023	Manns, R	0.30	Review and revise supplemental declaration.
11/06/2023	Manns, R	0.10	Emails with Debtors' financial advisor and working group regarding budget issues.
11/07/2023	Harrison, J	0.40	Review and revise BRG CNO (.1); related correspondence to M. Tehrani and M. Haverkamp (.2); file same with Court (.1).
11/08/2023	Manns, R	0.10	Review Committee call agenda.
11/09/2023	Manns, R	0.20	Review and respond to emails with Debtors' financial advisor regarding budgeting issues.
11/09/2023	Manns, R	0.50	Attend and participate on Committee call.
11/09/2023	Harrison, J	0.50	Attend UCC call.
11/09/2023	Harrison, J	0.20	Confer with R. Manns regarding supplemental declaration (.1); file same (.1).
11/09/2023	Harrison, J	0.20	Analysis of notice of hearing and calendar same.
11/10/2023	Adams, K	0.30	Review Scilex's Emergency Motion to Compel Production by Accounting Firm; organize calendar regarding same.
11/10/2023	Manns, R	0.30	Review and analyze Kilroy objection to confirmation.
11/10/2023	Manns, R	0.50	Review and analyze equity committee objection to plan.
11/14/2023	Manns, R	0.40	Review draft demand letters on Scilex and Directors and Officers.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	December 27, 2023	Invoice Number	9495495697	Page	3
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

11/15/2023	Manns, R	1.00	Attend hearing on Scilex 2004 motion.
11/16/2023	Harrison, J	0.20	Call with R. Manns regarding adjourned confirmation hearing (.1); analysis of notice regarding same (.1).
11/16/2023	Manns, R	0.80	Attend Committee call.
11/17/2023	Manns, R	0.20	Attention to Culberson confirmation objection.
11/17/2023	Manns, R	0.40	Analyze amended plan of liquidation.
11/17/2023	Adams, K	0.40	Review Modified Plan, Plan Supplement and Adjournment Notice; update calendars.
11/20/2023	Adams, K	0.30	Review Motion for Order Rejecting Research Collaboration Agreement; update information.
11/20/2023	Harrison, J	0.20	Analysis of voicemail from M. Probus (.1); and related correspondence with R. Manns (.1).
11/20/2023	Manns, R	0.20	Working group emails regarding communications with counsel for Scilex.
11/21/2023	Harrison, J	0.20	Call with M. Probus regarding 2004 exam (.1); related follow up with Milbank team (.1).
11/21/2023	Manns, R	0.20	Analyze complaint against JB Pacific for violation of the automatic stay.
11/21/2023	Manns, R	0.10	Attention to emails regarding case updates.
11/22/2023	Manns, R	0.20	Working group emails regarding revisions to October fee statement.
11/27/2023	Harrison, J	0.30	Confer with M. Tehrani and R. Manns regarding reply to EC objection (.2); file same with court (.1).
11/27/2023	Manns, R	0.10	Review third notice of filing of plan supplement.
11/27/2023	Manns, R	0.40	Review equity committee's objection to motion for protective order and confirmation.
11/27/2023	Manns, R	0.30	Review reply to Equity Committee plan objection.
11/28/2023	Manns, R	0.30	Review of equity committee's opposition to Debtors' counsel fee statement.
11/28/2023	Manns, R	0.40	Attend status conference.
11/28/2023	Manns, R	0.60	Review and analysis of Debtors' confirmation brief.
11/28/2023	Manns, R	0.30	Multiple working group emails regarding Committee w&e list (.2); review same in advance of filing (.1).
11/28/2023	Manns, R	0.20	Attention to Debtors' w&e list in advance of confirmation.

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.

Invoice Date	December 27, 2023	Invoice Number	9495495697	Page	4
Matter Number	1001247357				
Matter Description	Sorrento Therapeutics Bankruptcy				

11/28/2023	Harrison, J	0.20	Draft witness and exhibit list (.1); related correspondence with R. Manns (.1).
11/28/2023	Harrison, J	0.30	Attend emergency status conference.
11/28/2023	Adams, K	0.30	Review Notice of Status Conference; update calendars.
11/29/2023	Harrison, J	0.30	Draft monthly fee statement (.2); and related correspondence with R. Manns (.1).
11/29/2023	Manns, R	2.00	Travel for confirmation hearing.
11/29/2023	Manns, R	0.20	Attention to multiple working group emails regarding sale and confirmation updates.
11/30/2023	Harrison, J	3.30	Attend confirmation hearing.
11/30/2023	Manns, R	0.20	Attention to multiple working group email updates.
11/30/2023	Manns, R	2.00	Return travel to Dallas.
11/30/2023	Manns, R	3.50	Attend and appear at confirmation hearing.
Total		26.90	

Norton Rose Fulbright US LLP is a limited liability partnership registered under the laws of Texas.

Norton Rose Fulbright US LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP and Norton Rose Fulbright South Africa Inc are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at nortonrosefulbright.com.